$INM News

InMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine Pipeline

InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4

InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements

InMed Pharmaceuticals Inc. (INM) M&A Call Prepared Remarks Transcript

INM Stock Alert: What to Know as InMed, Mentari Announce Merger

/C O R R E C T I O N -- InMed Pharmaceuticals/

InMed-Mentari Migraine Merger Backed by $290 Million Financing Reshapes Company Strategy (INM)

Penny Stock InMed Pharmaceuticals Merger Deal Targets Migraine Pipeline

InMed Pharmaceuticals Amends Preferred Investment Options

UPDATE: InMed Pharmaceuticals To Merge With Mentari Therapeutics In All-Stock Deal Backed By $290M Private Placement, Combined Company Valued At $421.4M; InMed Shareholders to Own 1.51% Stake

InMed Pharmaceuticals To Merge With Mentari Therapeutics

InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Pharmaceuticals Amends Preferred Investment Options

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program

InMed Reports Preclinical Data Showing Reduced Brain Inflammation in Alzheimer's Models

InMed Pharmaceuticals Files Prospectus To Offer Up To $50M In Securities

InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline

On March 4, InMed Pharmaceuticals Confirmed And Approved The Decision To Wind Down BayMedica's Commercial Operations; BayMedica To Complete Wind Down Before Fiscal Year Ending June 30, 2026